Ebola vaccineJoe Segen2016-12-25T22:50:27+00:00
An Ebola vaccine produced from vesicular stomatitis virus–VSV, which causes an oral disease in cattle, but very rarely in humans. A single gene is removed from VSV, rendering it non-pathogenic to humans, and a single gene from Ebola virus is inserted. The inserted gene causes Ebola virus proteins to sprout from the surface.
Whilst these proteins do not cause Ebola, but they do evoke a protective immune response in 100% of tested primates.
The vaccine languished on a lab shelf for 10 years after development by Canadian scientists at the Public Health Agency’s National Microbiology Laboratory. It was licensed to NewLink Genetics, in Ames, Iowa in 2010 and, given the 2014 Ebola crisis, has been evaluated in 5 clinical trials.